JP2020530765A - リサウイルス抗原構築物 - Google Patents

リサウイルス抗原構築物 Download PDF

Info

Publication number
JP2020530765A
JP2020530765A JP2020502118A JP2020502118A JP2020530765A JP 2020530765 A JP2020530765 A JP 2020530765A JP 2020502118 A JP2020502118 A JP 2020502118A JP 2020502118 A JP2020502118 A JP 2020502118A JP 2020530765 A JP2020530765 A JP 2020530765A
Authority
JP
Japan
Prior art keywords
saturated
hydrocarbon chain
composition
rna
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020502118A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019016680A5 (enExample
Inventor
ヘイシー，キャスリン
マルヤラ，パドマ
サムサ，マルセロ
スラック，オルガ
ユー，ドン
ストークス，アラン
ジャラー，ラシュミ
Original Assignee
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グラクソスミスクライン バイオロジカルズ ソシエテ アノニム, グラクソスミスクライン バイオロジカルズ ソシエテ アノニム filed Critical グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Publication of JP2020530765A publication Critical patent/JP2020530765A/ja
Publication of JPWO2019016680A5 publication Critical patent/JPWO2019016680A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020502118A 2017-07-17 2018-07-16 リサウイルス抗原構築物 Pending JP2020530765A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762533312P 2017-07-17 2017-07-17
US62/533,312 2017-07-17
PCT/IB2018/055258 WO2019016680A1 (en) 2017-07-17 2018-07-16 ANTIGEN CONSTRUCTS OF LYSSAVIRUS

Publications (2)

Publication Number Publication Date
JP2020530765A true JP2020530765A (ja) 2020-10-29
JPWO2019016680A5 JPWO2019016680A5 (enExample) 2022-05-25

Family

ID=63364109

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020502118A Pending JP2020530765A (ja) 2017-07-17 2018-07-16 リサウイルス抗原構築物

Country Status (7)

Country Link
US (2) US11278613B2 (enExample)
EP (1) EP3655536A1 (enExample)
JP (1) JP2020530765A (enExample)
CN (1) CN111108203A (enExample)
BR (1) BR112020000802A2 (enExample)
CA (1) CA3070042A1 (enExample)
WO (1) WO2019016680A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022244815A1 (ja) * 2021-05-19 2022-11-24 第一三共株式会社 Ｈｐｖ感染症ワクチン
JP2024507482A (ja) * 2021-02-05 2024-02-20 イモーナ（ハンチョウ）バイオテクノロジー カンパニー リミテッド イオン化可能な脂質分子、その製造方法及び脂質ナノ粒子の製造における応用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110269933A (zh) * 2019-07-17 2019-09-24 苏州世诺生物技术有限公司 一种狂犬病毒亚单位疫苗的制备方法及其应用
CN110643632B (zh) * 2019-09-26 2022-06-10 中国科学院武汉病毒研究所 一种基于甲病毒复制子载体的狂犬病毒感染性克隆及制备方法和应用
WO2022077330A1 (zh) * 2020-10-15 2022-04-21 中国科学院深圳先进技术研究院 一种新型g基因及其在高效逆向跨单突触中的应用
US20220226465A1 (en) 2021-01-18 2022-07-21 ConserV Bioscience Coronavirus Immunogenic Compositions, Methods and Uses Thereof
WO2023031858A1 (en) 2021-09-01 2023-03-09 Glaxosmithkline Biologicals Sa Plasmid dna purification methods
TW202342753A (zh) * 2022-02-09 2023-11-01 大陸商蘇州艾博生物科技有限公司 狂犬病核酸疫苗
CN116120198B (zh) * 2022-03-21 2024-03-15 苏州科锐迈德生物医药科技有限公司 具有甘油骨架的脂质化合物及基于其的脂质载体、核酸脂质纳米粒组合物和药物制剂
CN116063410B (zh) * 2022-10-20 2023-07-14 北京标驰泽惠生物科技有限公司 一种狂犬病毒g蛋白的突变体及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010523086A (ja) * 2007-03-30 2010-07-15 ザ・リサーチ・ファウンデーション・オブ・ステート・ユニヴァーシティー・オブ・ニュー・ヨーク ワクチンに有用な弱毒化ウイルス
WO2015024665A1 (en) * 2013-08-21 2015-02-26 Curevac Gmbh Rabies vaccine
WO2016037053A1 (en) * 2014-09-05 2016-03-10 Novartis Ag Lipids and lipid compositions for the delivery of active agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3083556B1 (en) 2013-12-19 2019-12-25 Novartis AG Lipids and lipid compositions for the delivery of active agents
EP3083579B1 (en) 2013-12-19 2022-01-26 Novartis AG Lipids and lipid compositions for the delivery of active agents
CN110036020A (zh) * 2016-12-09 2019-07-19 葛兰素史密丝克莱恩生物有限公司 具有狂犬病病毒抗原的黑猩猩腺病毒构建体
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010523086A (ja) * 2007-03-30 2010-07-15 ザ・リサーチ・ファウンデーション・オブ・ステート・ユニヴァーシティー・オブ・ニュー・ヨーク ワクチンに有用な弱毒化ウイルス
WO2015024665A1 (en) * 2013-08-21 2015-02-26 Curevac Gmbh Rabies vaccine
WO2016037053A1 (en) * 2014-09-05 2016-03-10 Novartis Ag Lipids and lipid compositions for the delivery of active agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ADVANCES IN GENETICS, vol. Vol.89, pp.179-233, JPN6022022341, 2015, ISSN: 0005080506 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024507482A (ja) * 2021-02-05 2024-02-20 イモーナ（ハンチョウ）バイオテクノロジー カンパニー リミテッド イオン化可能な脂質分子、その製造方法及び脂質ナノ粒子の製造における応用
JP7683017B2 (ja) 2021-02-05 2025-05-26 イモーナ（ハンチョウ）バイオテクノロジー カンパニー リミテッド イオン化可能な脂質分子、その製造方法及び脂質ナノ粒子の製造における応用
WO2022244815A1 (ja) * 2021-05-19 2022-11-24 第一三共株式会社 Ｈｐｖ感染症ワクチン

Also Published As

Publication number Publication date
US11278613B2 (en) 2022-03-22
US20220241398A1 (en) 2022-08-04
US20200222526A1 (en) 2020-07-16
CA3070042A1 (en) 2019-01-24
BR112020000802A2 (pt) 2020-07-21
WO2019016680A1 (en) 2019-01-24
CN111108203A (zh) 2020-05-05
EP3655536A1 (en) 2020-05-27

Similar Documents

Publication Publication Date Title
US20220241398A1 (en) Lyssavirus antigen constructs
US20250064916A1 (en) Immunogenic compositions and uses thereof
US20230256083A1 (en) Self-amplifying sars-cov-2 rna vaccine
JP2022511980A (ja) 異種プライムブーストワクチン組成物及び方法
US20190134184A1 (en) Zika viral antigen constructs
ES2921605T3 (es) Vacuna contra el virus de la encefalitis equina basada en el virus de la variolovacuna modificado Ankara (VMA) recombinante
Gergen et al. mRNA-based vaccines and mode of action
EP4043031A1 (en) Zika viral antigen constructs
US20240181038A1 (en) Immunogenic compositions
TW202417018A (zh) 編碼流感病毒抗原之自擴增rna
Wei et al. Technological breakthroughs and advancements in the application of mRNA vaccines: a comprehensive exploration and future prospects
Koppu et al. Current perspectives and future prospects of mRNA vaccines against viral diseases: a brief review
US20220023413A1 (en) Recombinant mumps virus vaccine expressing genotype g fusion and hemagglutinin-neuraminidase proteins
EP4661903A1 (en) Nucleic acids and uses thereof
HK40073646A (en) Zika viral antigen constructs

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220517

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220905

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230406

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230406

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230413

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230418

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230609